The pharmaceutical industry says it is "very relieved" that the ongoing EU signal detection pilot involving the revamped EudraVigilance database – which was due to end after one year of operation on Feb. 22, 2019 – has been extended until further notice, but it is making a case to ensure it does not move into the next implementation phase until there are meaningful data to demonstrate its benefits.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?